CNSide Signs National Aetna Payer Agreement
Cerenome subsidiary CNSide Diagnostics secures in-network reimbursement with Aetna Health Plans effective November 1, 2026.
Updated on Nov. 4, 2026 in Healthcare
Live Poll
Do you trust your health insurer to cover the cancer tests your doctor orders?
CNSide Diagnostics, a wholly-owned subsidiary of Cerenome, Inc., has entered a national in-network agreement with Aetna Health Plans, effective November 1, 2026. The agreement establishes contracted reimbursement for CNSide's tumor cell enumeration and molecular profiling tests for central nervous system cancers.
Why it matters
The agreement adds approximately 26 million Aetna medical members to CNSide's contracted payer footprint, expanding patient access to the company's CSF testing. It is the first national CNSide payer agreement to include both tumor cell enumeration and molecular profiling.
CNSide's in-network agreements now represent approximately 190 million covered lives, with Aetna's roughly 26 million medical members added to that total. Cerenome is contracted with about 85% of private US payers, though the agreement's financial terms were not disclosed.
The players
Cerenome, Inc.
Cerenome is the parent company of CNSide Diagnostics and holds contracts with approximately 85% of private payers in the United States.
CNSide Diagnostics
CNSide Diagnostics is a wholly-owned subsidiary of Cerenome that offers cerebrospinal fluid tumor cell enumeration and molecular profiling tests.
Aetna Health Plans
Aetna is a major US health insurer serving an estimated 37 million people.
The details
The agreement covers the CNSide CSF Tumor Cell Enumeration test and CNSide CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions, and a peer-reviewed real-world study evaluated 1,391 evaluable CSF specimens.
Timeline
November 1, 2026: Aetna agreement becomes effective.
November 4, 2026: Agreement announced publicly.
Industry Position
The agreement extends commercial reimbursement for CNSide's cerebrospinal fluid tumor cell enumeration and molecular profiling tests, which have been used at more than 120 U.S. cancer institutions since 2020. It moves CNSide's CSF testing from institutional use toward broader payer coverage across national commercial insurance.
Patients covered by Aetna may have access to CNSide's CSF tumor testing under the new in-network agreement beginning November 1, 2026. Cost-sharing and eligibility will depend on individual plan terms, which the agreement announcement did not detail.
The takeaway
Patients with central nervous system cancers should ask their oncologist whether CSF testing is appropriate and check their Aetna plan for coverage details. Coverage under in-network agreements can vary by plan, so confirming benefits before testing is advisable.
Further reading
For more on the sector, see the Healthcare coverage on payer and diagnostics developments across the country.
More information
Learn more on the CNSide diagnostics information page.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust your health insurer to cover the cancer tests your doctor orders?
